Dongguan Kewei Wins the Second Prize of State Science and Technology Progress Award for the Project "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery"

Beijing, China – On January 9, Dongguan Kewei Medical Instrument Co., Ltd. ("Dongguan Kewei"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), won the second prize of State Science and Technology Progress Award together with the Fourth Military Medical University for the project "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" they jointly developed. A total of 33 projects of healthcare and medical industry received the State Science and Technology Awards, according to the list released during the 2016 National Science and Technology Award Ceremony.
Funded by the National Key Technology Research and Development Program of China during the "10th Five-Year Plan," the project "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" is a fruit of series of studies conducted by Dongguan Kewei and the Fourth Military Medical University on the new technologies, new devices, new products and new strategies of minimally invasive cardiac surgery. The project team took the lead in developing the new technology of cardiovascular disease interventional therapy guided by transthoracic ultrasound. They are also the first to use total endoscopic cardiac surgery techniques and created new technologies of minimally invasive cardiac surgery compound operation, as well as adenosyl-CTRP myocardial preservation. They established a new system of minimally invasive cardiac surgery technologies to carry out the conversion from open surgery repair to minimally invasive therapy with the rate of minimally invasive surgery increased to 56%. They treated 35,959 cases of cardiac diseases with the new technology in 64 top hospitals in China and achieved the success rate of 99.6%. In addition, the team developed the new type of occlude for the minimally invasive cardiac surgery and designed innovative arteriovenous catheters, which are also the main products and key technologies of Dongguan Kewei with two national invention patents and 33 patents for inventions, utility models and design.
Meanwhile, the project team established the National Cardiac Intervention Training Center and the Minimally Invasive Cardiac Surgery Training Base, which so far have organized 46 training courses, developed 43 researchers, trained 1,672 professionals, and completed operation demonstrations for 67 cardiac surgeons from 16 countries in Europe, North America and Asia, making valuable contributions to the development of China's minimally invasive cardiac surgical treatment.
Currently, Dongguan Kewei has set up high-standard production base mainly for its intervention and extracorporeal circulation products. With 17 certificates from China Food and Drug Administration and nine registration certificates from regulatory bodies in Russia, India, and European countries, its products are sold to and widely used in 455 leading hospitals in China as well as hospitals in more than ten countries or regions in Europe, South America and Southeast Asia, to help millions of patients alleviate pain as well as to generate economic benefits for Dongguan Kewei.
In the future, MicroPort® will continue to carry out our mission that "We Continuously Innovate and Subsequently Commercialize the Best and Yet Affordable Therapeutic Solutions to Save and Reshape Lives," and to build a brand reflecting our ideology "The Patient Always Comes First" with high-quality products, technological invention and constantly improving innovative capability.